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A multicenter experience of the management of
collapsed thoracic endografts
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Objectives: Thoracic endograft collapse after thoracic endovascular aortic repair (TEVAR) is a potentially devastating
complication. This study evaluates the management of thoracic stent graft collapse.
Methods: A multicenter review of thoracic stent graft collapse was performed from 2005 to 2009. Diagnosis and
preoperative planning was performed by computed tomography angiography (CTA). Outcomemeasures included success
of endovascular salvage, postoperative complications, and conversion to open repair.
Results: Eleven patients (10 men) with thoracic endograft collapse were identified. Mean age was 41.2 years old (range,
21-66 years). Indications for the index TEVAR were traumatic aortic transections in 8 patients and acute type B
dissections in 3 patients. All were initially treated with the TAG endoprosthesis (Gore and Associates, Flagstaff, Ariz).
The median duration from initial repair to diagnosis of collapse was 9 days (range, 1 day-38 months). All collapses were
initially treated by endovascular means using another TAG device in 7 patients, a Talent (Medtronic, Santa Rosa, Calif)
thoracic stent graft in 3 patients, and a Palmaz (Cordis Endovascular, Warren, NJ) stent in 1 patient. In 1 patient, the
secondary TAG did not resolve the collapse and required a Palmaz stent placement. Technical success rate was 91%, while
re-expansion of the collapsed endograft was achieved in all patients. Early and late complications were observed in 3
patients. Delayed (>30 days) open conversion with device explantation was performed for an aortoesophageal fistula,
physiological aortic coarctation, and prevention of a recurrent collapse in 1 patient each. There were no perioperative
deaths or recurrent collapses.
Conclusion: Endograft collapse can be successfully managed by endovascular techniques in most cases. Redo-TEVAR
using high radial force devices should be considered the initial treatment of choice. Late endograft-related complications
after treatment of collapsed endografts are not uncommon and can be safely managed by open conversion. (J Vasc Surg
2011;53:1217-22.)
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fiThoracic endovascular aortic repair (TEVAR) has been
established as the preferential therapeutic modality for
treatment of intact aneurysms of the descending thoracic
aorta given its superior early and late outcomes compared
with direct open repair.1-4 Its application has also gained a
wide acceptance to treatment of acute thoracic aortic pa-
thologies based on its favorable outcomes in comparison to
open repair.5,6 However, to date, there exist no commer-
cially available devices that are pathology-specific and satisfy
the differential engineering considerations for the spectrum
of thoracic aortic pathologies.
Rare, but increasingly noted endograft-related compli-
cations, physiological aortic coarctation, and endograft col-
lapse have been reported when used for, although not
specific to, nonaneurysmal pathologies.7-16 These compli-
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doi:10.1016/j.jvs.2010.10.119ations can lead to devastating consequences, including
eperfusion of the injured or dissected aortic segment and
nd-organ malperfusion. Herein, a multicenter experience
ith collapsed thoracic endografts and its management are
eported.
ETHODS
A retrospective chart review of medical records at the
niversity of Pittsburgh Medical Center (Pittsburgh, Pa),
ount Sinai Medical Center (New York, NY), and Mon-
efiore Medical Center (Bronx, NY) identified 11 patients
ho presented with thoracic endograft collapse from Jan-
ary 2005 to December 2009. The initial TEVAR was
onsidered as the index procedure. All stent graft collapses
ere confirmed by computed tomographic angiography
CTA). This study was approved by the Institutional Re-
iew Board of each respective institution.
Baseline patient characteristics and perioperative vari-
bles were evaluated, including the type of device used,
ength of aortic coverage, and adjunctive procedures used.
ostoperative follow-up data were also collected. Clinical
utcomes, including endograft salvage and graft-related
omplications were recorded.
Postoperative imaging (CTA) protocol varied slightly
mong the institutions, but in general it was obtained
efore discharge, and then at 1 month, 3 months, and then
nnually thereafter, unless otherwise indicated as per CT
ndings or clinical suspicion. The method of repair (endo-
ascular vs open) was determined by the operating surgeon.
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Eleven patients (10 men and 1 women) with thoracic
endograft collapse were identified (Table I) from a prospec-
tively collected database from each institution. The distri-
bution of cases from each institution is detailed in Table I.
The total numbers of TEVAR cases done during the study
period at each institution are as follows: the University of
Pittsburgh, 120; Mount Sinai, 81; and Montefiore, 51; of
which 43, 6, and 3 were for traumatic aortic transections
from the respective institutions. The mean age was 41.2
years (range, 21-66 years). The indications for the index
TEVAR were traumatic aortic transection in 8 patients and
acute complicated type B aortic dissection in 3 patients. All
patients were initially treated with TEVAR using the TAG
endoprosthesis (Gore and Associates, Flagstaff, Ariz). The
left subclavian artery (LSA) was covered in 2 patients and
with concomitant revascularization in 1 patient. In the
other patient (patient #9), a left common carotid artery
(LCCA) to LSA bypass was performed 1 month later to
preserve a left arm hemodialysis access arteriovenous fistula
(Table II). An iliac conduit was used in 1 patient only.
The median duration from the time of the index TE-
VAR to the recognition of stent graft collapse was 9 days
(range, 1 day-38months; Table II); 8 of the 11 patients had
the collapse diagnosed within 30 days of and during the
same hospitalization of the device implantation. Endograft
collapse occurred in the proximal segment in 10 patients and
in the distal part in 1 patient. Most of the collapses were
asymptomatic and detected by routine imaging studies; symp-
toms were present in only 4 patients (36.4%; Table II).
All collapses were initially treated by endovascular
means and re-expansion was achieved in all patients. In 1
patient, an additional TAG device did not achieve re-
Table I. Patient characteristics, aortic pathology, and inde
Pt # Age Gender Aortic pathology
Initial dev
(mm
1 (RI) 21 M Traumatic TBAD
(pseudoaneurysm)
TAG 26 
2 (MS) 66 F TAT TAG 34 
26  10
3 (MS) 21 M TAT TAG 28 
4 (MF) 34 M TAT TAG 26 
5 (UP) 50 M TAT TAG 28 
6 (UP) 21 M TAT TAG 26 
7 (UP) 43 M TAT TAG 28 
8 (UP) 41 M TAT TAG 28 
9 (RI) 36 M TAT TAG 26 
10 (UP) 63 M Spontaneous TBAD
(rupture)
TAG 34 
11 (UP) 57 M Spontaneous TBAD
(refractory pain)
TAG 31 
F, Female; LCCA, left common carotid artery; LSA, left subclavian artery; M
referring institution; TAT, traumatic aortic transection; TBAD, type B aort
Pittsburgh Medical Center.expansion, thereby requiring a Palmaz stent (Cordis Endo- aascular, Warren, NJ) placement as detailed below. Tech-
ical success rate was 91% (10 of 11).
High radial force devices were used in 4 patients: the
alent thoracic stent grafts (Medtronic, Santa Rosa, Calif)
n 3 patients and the Palmaz stents in 1 patient, with
uccessful re-expansion in all. The TAG endograft was used
n the remaining 7 patients with re-expansion achieved in 6
atients. The 1 patient (patient #11) with a persistent
ollapse, initially had undergone a TEVAR using a TAG
evice for an acute type B dissection. The patient was noted
o have a collapse and underwent an additional TAG place-
ent 3 days later. A persistent collapse was noted on a
ollow-up CTA, and the patient was treated with a Palmaz
tent 4 days later. An unrecognized iatrogenic injury in the
scending aorta had occurred at the time of Palmaz place-
ent (Fig 1) that was not detected until 8 days later. The
atient underwent an uncomplicated open repair of type A
issection with preservation of the endograft. Two patients
ad LSA coverage at the secondary intervention without its
evascularization. Balloon angioplasty was initially at-
empted in 5 patients but was successful in none.
There were no mortalities with re-expansion achieved
n all patients. The cumulative complication rate was 27% (3
f 11). Early (30 days) complications occurred in 1
atient: persistent collapse and an iatrogenic type A dissec-
ion as detailed above. Late (30 days) graft-related com-
lications, an aortoesophageal fistula, and a physiological
oarctation developed at 1 month and 7 months after
econdary TEVAR, respectively; these were successfully
reated by open conversion with device explantation as
eported earlier.7,17
Endograft preservation was achieved in 8 patients
72.7%). In addition to the 2 aforementioned patients, 1
VAR
d size
)
Proximal
aortic
diameter
Proximal
landing
zone LSA revascularization?
24 3 No
1  10, 28 3 No
24 3 No
20 3 No
23 3 No
6  10 22 3 No
24 3 No
24 3 No
28 2 LCCA-LSA bypass 1 month
later for salvage of L arm
arteriovenous fistula
7  10 32 2 LSA-LCCA transposition
for type I endoleak
28 3 No
le; MF, Montefiore Medical Center; MS, Mount Sinai Medical Center; RI,
ection; TEVAR, thoracic endovascular aneurysm repair; UP, University ofx TE
ice an
 cm
10
10, 3
10
10
15
10, 2
10
10
10
15, 3
10
, madditional patient underwent elective open conversion.
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Volume 53, Number 5 Tadros et al 1219This patient (patient #9) presented with symptomatic en-
dograft collapse: complete bilateral lower extremity motor
and sensory loss and bowel incontinence. He underwent an
emergency redo-TEVAR by proximal extension with par-
tial coverage of the common origin of the brachiocephalic
and the LCCA (bovine arch) with resolution of the collapse
and full neurologic recovery.18 However, a severe “bird-
beak” was noted on completion aortography (Fig 2). The
patient was advised to undergo elective open conversion
with device explantation lest collapse may recur with dev-
astating neurologic sequelas. He tolerated the procedure
well 2 weeks later without any complications.
Not all patients who have undergone open conversion
experienced any further complications at last follow-up. No
recurrent collapses have been noted after secondary TE-
VAR at a mean follow-up of 8.7 months.
DISCUSSION
This study represents the largest series of thoracic stent
graft collapse, a rare but well-known complication of TE-
VAR. Although thoracic stent graft collapse can occur after
Table II. Treatment for collapse and clinical outcomes
Pt #
Time
interval:
TEVAR to
collapse
Collapse
site
Sx/findings with
collapse T
1 (MS) 30 days Proximal Lower extremity
malperfusion
Talent, p
withou
2 (MS) 2 days Proximal None Talent, p
with L
3 (MS) 7 days Proximal Lower extremity
malperfusion
Talent, p
withou
4 (MF) 20 days Proximal None Palmaz, p
extensi
covera
5 (UP) 5 months Proximal Chest pain TAG, pro
with L
6 (UP) 32 days Proximal None TAG, pro
with L
7 (UP) 23 days Proximal None TAG, wit
extensi
8 (UP) 8 days Proximal None TAG, wit
extensi
9 (UP) 38 months Proximal Paraplegia
(resolved)
TAG, wit
extensi
“bird-b
10 (UP) 1 day Mid None TAG, wit
extensi
11 (UP) 3 days Proximal None TAG  P
withou
extensi
extensi
AEF, Aortoesophageal fistula; LSA, left subclavian artery; MF,Montefiore M
aneurysm repair; UP, University of Pittsburgh Medical Center.
aFollow-up from open conversion.TEVAR is performed for aneurysmal disease, it does occur qore commonly after treatment for traumatic aortic tran-
ection or spontaneous aortic dissection. This can be attrib-
ted to the difference in aortic morphology and the lack of
ommercially available disease-specific endografts.
The use of TEVAR has emerged as the preferred
ethod of treatment for traumatic aortic transections and
omplicated type B dissections. These conditions, despite
he lack of endografts, meet their disease-specific consider-
tions and have experienced improved outcomes with en-
ovascular treatment as compared to conventional surgical
epair.19-22 TEVAR can be performed quickly, safely, and
ith the patient under local anesthesia without systemic
eparinization, which can be advantageous in patients with
leeding concerns.17 Demetriades et al22 demonstrated a
ignificantly increased mortality rate (age-adjusted and in-
ury severity-adjusted odds ratio of 8.4) in patients treated
ith open surgical repair compared with TEVAR.
Clearly, TEVAR has added a valuable treatment op-
ion to the armamentarium used in the management of
he spectrum of thoracic aortic pathologies. However,
evice-related complications may occur and often re-
ent Complications
Endograft
salvage?
Follow-up
duration
from
secondary
procedure
al extension
coverage
None Yes Lost to
follow-up
al extension
verage
None Yes 2 months
al extension
coverage
None Yes 3 months
al
ithout LSA
None Yes Lost to
follow-up
l extension
verage
AEF No,
explanted
4.3 yearsa
l extension
verage
Physiological aortic
coarctation
No,
explanted
1.2 yearsa
proximal None Yes 1 year
proximal None Yes Lost to
follow-up
ximal
evere
)
None No,
explanted
3 monthsa
proximal None Yes 4 months
z proximally
ximal
AG distal
Failure to open the
collapse with
TAG; type A
dissection with
Palmaz (treated
with open
repair)
Yes 6 months
l Center; MS,Mount Sinai Medical Center; TEVAR, thoracic endovascularreatm
roxim
t LSA
roxim
SA co
roxim
t LSA
roxim
on w
ge
xima
SA co
xima
SA co
hout
on
hout
on
h pro
on (s
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on
alma
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May 20111220 Tadros et alparticular occurs more commonly after treatment of
aortic dissection or transection,23 a finding corroborated
in our review of institutional experiences. Although its
true incidence is not well-defined due to poor follow-up of
trauma patients in whom the majority of transection oc-
curs, the reported incidences range from 1.4% to 19% in
Fig 1. An iatrogenic aortic dissection of the ascending aorta
(arrow). This was not recognized until 8 days later.
Fig 2. An additional Gore TAG endoprosthesis was placed to
re-expand the collapse. However, a severe “bird-beak” is noted
(arrow).reported case series.10,15,16,24 Although asymptomatic in tost cases,8,11,12,15,24,25 the collapse may pose a signifi-
ant risk, namely reperfusion of the injured or dissected
ortic segment or aortic occlusion, and distal end-organ
alperfusion syndrome.
Stent graft collapse after TEVAR may be caused by a
umber of anatomic- and device-related factors. It may
ccur with all devices, although most commonly described
ith the TAG endoprosthesis.14,16,26 This is not a unique
roblem to the Gore TAG device and has been reported
ith other endografts, including the Zenith TX2 (Cook
edical Inc, Bloomington, Ind) and the EndoFit (Le-
aitre Vascular, Burlington, Mass). The underlying
echanism of endograft collapse is multifactorial and
ncludes a tight aortic arch, a narrow aortic diame-
er,11,12,23 endograft oversizing,11,16,24,25 a “bird-beak”
henomenon,10,24 low radial force devices,11,12,23,24 ma-
erial fatigue,14 and young healthy aorta.16 Muhs et al,23 in
heir series of six stent graft collapses, noted that no collapse
ccurred in patients with an aortic diameter of 23 mm,
nd that the sealing zone aortic diameter and the minimum
ortic diameter, and not the percentage of oversizing, were
redictive of stent graft collapse; they warned against the
se of the TAG device in aortas smaller than 23 mm in
iameter. However, the data from the current series and
thers indicate that the collapse can occur even when the
reated aortic diameter is23mm.12,24,25 Although exces-
ive oversizing (even up to 90% has been reported23) has
een attributed to the collapse,11,23,24 it has been shown to
ccur even with proper sizing.12,24-26 Canaud et al24 found
cute aortic arch angulation and poor apposition of the
tent graft to the inner curve of the arch to be associated
ith the collapse in their review of 4 cases. Neschis et al,27
n a review of 43 consecutive TEVARs for traumatic aortic
ransection, determined that all 4 patients who developed
evice-related complications (including two collapses) had
he site of aortic injury within 2 cm of the LSA with the
harpest bend in the descending thoracic aorta between the
SA and the tear.
The management of thoracic endograft collapse in-
ludes redo-TEVAR and open surgical repair. This can
esult in significant morbidity and mortality, especially in
ymptomatic patients. Canaud et al,24 in a review of 29
ases reported in the literature, noted a 6.8%mortality both
f which occurred in symptomatic patients.15 They also
oted in their series of 7 cases that all 3 patients with
ymptomatic collapse either died (2 patients) or suffered
evere complications (renal failure, bowel ischemia, and
araparesis).15 Open thoracotomy, although definitive, can
e associated with major complications even in young
atients. If the collapse occurs in the early postprocedural
eriod, which is predominantly the case, endovascular sal-
age is more desirable as the attendant risks of open surgery
ay be higher, especially in patients with multiple trau-
atic injuries. In addition, if the patient presents with
ymptoms, an endoluminal therapy may provide a quicker
olution than direct open repair.
The goal of endovascular repair should be to increase
he radial force at the locus of collapse and improve appo-
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Volume 53, Number 5 Tadros et al 1221sition to the aortic wall. This can be achieved by placement
of a large balloon-expandable stent, such as the Palmaz
stent, without proximal extension into the native aorta.
Simple balloon angioplasty alone is not effective; it may
temporarily open the endograft, but it collapsed again after
a few cardiac cycles. Deployment of a Palmaz stent into the
uncovered aorta should be avoided to prevent a retrograde
type A dissection or injury to the aortic arch.12 Catheter-
related or wire-related injury to the ascending aorta may
also result in a type A dissection, as was observed in this
series. Due precautions should be taken to avoid such an
outcome.
Alternatively, additional endograft placement with or
without proximal extension can be performed.11,12,15,27
Proximal extension, while not always necessary, can be
achieved when a sufficient neck is available. In this series,
proximal extension was performed in 4 patients with cov-
erage of the LSA in 3 patients; in 1 patient, the LSA had
been covered at the initial repair.While coverage of the LSA
is commonly reported and well tolerated, graft extension
across the LCCA should be discouraged in young patients
who have an otherwise normal life expectancy.12 When
such is needed, open conversion should be strongly consid-
ered if the patient is fit.
Open conversion should also be considered when ad-
ditional endograft or Palmaz stent deployment leaves any
concern for recurrent collapse or when late device-related
complications develop. Ideally, this can be done safely
when the patient has recovered fully from the initial trau-
matic injuries.7,25 All 3 patients in this series who under-
went late conversion tolerated it well without any compli-
cations. It is also of interest to note that all these patients
had late (30 days) stent graft collapse.
There are several limitations to this study inherent to its
multicenter, retrospective design. The number of patients
was small and thereby limiting. Follow-up data are also
limited and thus preclude drawing any conclusions on
long-term performance of redo-TEVAR for the collapse.
The findings of this study relate to the Gore TAG device, as
the authors have not seen any collapses with other devices
as yet. As such, the observations and findings of this study
may not be applicable to other devices.
CONCLUSIONS
Endograft collapse after TEVAR can be successfully
managed by endovascular techniques in the majority of
cases. Redo-TEVAR using high radial force devices should
be considered the initial treatment of choice as the technical
success is improved with reduced morbidity. Failure of
endovascular salvage of collapsed endografts and late graft-
related complications can be effectively and safely managed
with open repair without significantly added morbidity or
mortality. Delayed graft collapse can occur and warrants
ongoing surveillance. Late outcomes of endovascular treat-
ment of collapse remain to be determined.UTHOR CONTRIBUTIONS
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